Overview

Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer

Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
To determine the safety, feasibility and appropriate dendritic cell dose to vaccinate patients with pancreas cancer
Phase:
Phase 1
Details
Lead Sponsor:
George Albert Fisher
Treatments:
Gemcitabine